» Articles » PMID: 34064122

Design, Radiosynthesis and Preliminary Biological Evaluation in Mice of a Brain-Penetrant F-Labelled σ Receptor Ligand

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jun 2
PMID 34064122
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The σ receptor (transmembrane protein 97), which is involved in cholesterol homeostasis, is of high relevance for neoplastic processes. The upregulated expression of σ receptors in cancer cells and tissue in combination with the antiproliferative potency of σ receptor ligands motivates the research in the field of σ receptors for the diagnosis and therapy of different types of cancer. Starting from the well described 2-(4-(1-indol-1-yl)butyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline class of compounds, we synthesized a novel series of fluorinated derivatives bearing the F-atom at the aromatic indole/azaindole subunit. (2-[4-(6-fluoro-1-pyrrolo[2,3-b]pyridin-1-yl)butyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline) was selected for labelling with F and evaluation regarding detection of σ receptors in the brain by positron emission tomography. Initial metabolism and biodistribution studies of [F] in healthy mice revealed promising penetration of the radioligand into the brain. Preliminary in vitro autoradiography on brain cryosections of an orthotopic rat glioblastoma model proved the potential of the radioligand to detect the upregulation of σ receptors in glioblastoma cells compared to healthy brain tissue. The results indicate that the herein developed σ receptor ligand [F] has potential to assess by non-invasive molecular imaging the correlation between the availability of σ receptors and properties of brain tumors such as tumor proliferation or resistance towards particular therapies.

Citing Articles

Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment.

Huang X, Zhu X, Yang H, Li Q, Gai L, Sui X Molecules. 2024; 29(7).

PMID: 38611742 PMC: 11012694. DOI: 10.3390/molecules29071462.


The Sigma Receptors in Alzheimer's Disease: New Potential Targets for Diagnosis and Therapy.

Wang T, Jia H Int J Mol Sci. 2023; 24(15).

PMID: 37569401 PMC: 10418732. DOI: 10.3390/ijms241512025.


Development of Fluorescent 4-[4-(3-Spiro[isobenzofuran-1,4'-piperidin]-1'-yl)butyl]indolyl Derivatives as High-Affinity Probes to Enable the Study of σ Receptors via Fluorescence-Based Techniques.

Abatematteo F, Majellaro M, Montsch B, Prieto-Diaz R, Niso M, Contino M J Med Chem. 2023; 66(6):3798-3817.

PMID: 36919956 PMC: 10041534. DOI: 10.1021/acs.jmedchem.2c01227.


Radiosynthesis and Preclinical Evaluation of an F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A).

Wenzel B, Fritzsche S, Toussaint M, Briel D, Kopka K, Brust P Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297384 PMC: 9609767. DOI: 10.3390/ph15101272.

References
1.
Bautista-Aguilera O, Budni J, Mina F, Medeiros E, Deuther-Conrad W, Entrena J . Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile. J Med Chem. 2018; 61(15):6937-6943. DOI: 10.1021/acs.jmedchem.8b00848. View

2.
Yang K, Zeng C, Wang C, Sun M, Yin D, Sun T . Sigma-2 Receptor-A Potential Target for Cancer/Alzheimer's Disease Treatment via Its Regulation of Cholesterol Homeostasis. Molecules. 2020; 25(22). PMC: 7699687. DOI: 10.3390/molecules25225439. View

3.
Kawamura K, Kubota K, Kobayashi T, Elsinga P, Ono M, Maeda M . Evaluation of [11C]SA5845 and [11C]SA4503 for imaging of sigma receptors in tumors by animal PET. Ann Nucl Med. 2006; 19(8):701-9. DOI: 10.1007/BF02985120. View

4.
Waterhouse R . Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003; 5(6):376-89. DOI: 10.1016/j.mibio.2003.09.014. View

5.
Nicholson H, Mesangeau C, McCurdy C, Bowen W . Sigma-2 Receptors Play a Role in Cellular Metabolism: Stimulation of Glycolytic Hallmarks by CM764 in Human SK-N-SH Neuroblastoma. J Pharmacol Exp Ther. 2015; 356(2):232-43. PMC: 4746495. DOI: 10.1124/jpet.115.228387. View